<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(1)</volume><submitter>Nguyen NTB</submitter><pubmed_abstract>Therapeutic antibodies are decorated with complex-type N-glycans that significantly affect their biodistribution and bioactivity. The N-glycan structures on antibodies are incompletely processed in wild-type CHO cells due to their limited glycosylation capacity. To improve N-glycan processing, glycosyltransferase genes have been traditionally overexpressed in CHO cells to engineer the cellular N-glycosylation pathway by using random integration, which is often associated with large clonal variations in gene expression levels. In order to minimize the clonal variations, we used recombinase-mediated-cassette-exchange (RMCE) technology to overexpress a panel of 42 human glycosyltransferase genes to screen their impact on antibody N-linked glycosylation. The bottlenecks in the N-glycosylation </pubmed_abstract><journal>Scientific reports</journal><pagination>12969</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8217518</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex-type N-glycans.</pubmed_title><pmcid>PMC8217518</pmcid><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Mariati</pubmed_authors><pubmed_authors>Yeo J</pubmed_authors><pubmed_authors>Nguyen NTB</pubmed_authors><pubmed_authors>Lin J</pubmed_authors><pubmed_authors>Nguyen-Khuong T</pubmed_authors><pubmed_authors>Tay SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex-type N-glycans.</name><description>Therapeutic antibodies are decorated with complex-type N-glycans that significantly affect their biodistribution and bioactivity. The N-glycan structures on antibodies are incompletely processed in wild-type CHO cells due to their limited glycosylation capacity. To improve N-glycan processing, glycosyltransferase genes have been traditionally overexpressed in CHO cells to engineer the cellular N-glycosylation pathway by using random integration, which is often associated with large clonal variations in gene expression levels. In order to minimize the clonal variations, we used recombinase-mediated-cassette-exchange (RMCE) technology to overexpress a panel of 42 human glycosyltransferase genes to screen their impact on antibody N-linked glycosylation. The bottlenecks in the N-glycosylation </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2026-05-08T01:20:33.797Z</modification><creation>2022-02-10T16:41:32.625Z</creation></dates><accession>S-EPMC8217518</accession><cross_references><pubmed>34155258</pubmed><doi>10.1038/s41598-021-92320-x</doi></cross_references></HashMap>